Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FAM181A antisense RNA 1 (FAM181A-AS1) is a long non-coding RNA (lncRNA) transcribed from the antisense strand relative to the FAM181A gene and located on human chromosome 14. It does not encode a protein but appears to regulate gene expression and cellular processes via regulatory RNA mechanisms, such as acting as a competitive endogenous RNA (“sponge”) for microRNAs. FAM181A-AS1 has been identified as a potential prognostic biomarker in several cancers, notably glioma (where it promotes tumor growth by sponging miR-129-5p and upregulating ZRANB2 expression) and lung adenocarcinoma (where low expression correlates with poorer survival and altered immune infiltration). Its functions include potential involvement in the regulation of the cell cycle, DNA repair, chromatin modification, immune cell infiltration, and cellular senescence. There is no evidence that FAM181A-AS1 is a therapeutic target for drugs or that it is considered a receptor, enzyme, transporter, or typical pharmacological target[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FAM181A antisense RNA 1 (FAM181A-AS1).